
Health Dictionary
Reliable, easy-to-read patient information on common medical conditions — written in plain language, free of jargon, and grounded in current evidence. Browse the most frequent diagnoses, understand what they mean for everyday life, and learn which steps and questions help you have a focused conversation with your doctor.
Cephalexin how supplied
Introduction
| Cephalexin |
|---|
| CEPHALEXIN®,KEFLEX® FDA Package Insert |
| Description |
| Clinical Pharmacology |
| Microbiology |
| Indications and Usage |
| Contraindications |
| Warnings and Precautions |
| Adverse Reactions |
| Overdosage |
| Dosage and Administration |
| How Supplied |
| Labels and Packages |
Cephalexin capsules USP—
250 mg: Swedish orange body and gray cap imprinted “TEVA” on the cap and “3145” on the body, in bottles of 100, 500, and unit-dose boxes of 100 (10 x 10).
500 mg: Swedish orange body and Swedish orange cap imprinted “TEVA” on the cap and “3147” on the body, in bottles of 100, 500, and unit-dose boxes of 100 (10 x 10).
Store at 20° to 25°C (68° to 77°F) [See USP Controlled Room Temperature].
Cephalexin for oral suspension* USP
(a cherry mixed fruit flavored formula)—
125 mg/5 mL: bottles of 100 mL and 200 mL.
250 mg/5 mL: bottles of 100 mL and 200 mL.
Directions for mixing are included on the label.
Store at 20° to 25°C (68° to 77°F) [See USP Controlled Room Temperature].
Shake well before using. Keep tightly closed.
- After mixing, store in refrigerator. May be kept for 14 days without significant loss of potency.
Cephalexin tablets USP—
250 mg: bottles of 100. Tablet identification number and color: white, capsule-shaped tablet, debossed “2238” on one side with a score between the “2” and the “3” and “TEVA” on the reverse side.
500 mg: bottles of 100. Tablet identification number and color: white, capsule-shaped tablet, debossed “2240” on one side with a score between the “2” and the “4” and “TEVA” on the reverse side.
Store dry powder at 20° to 25°C (68° to 77°F) [See USP Controlled Room Temperature].
References
http://www.accessdata.fda.gov/drugsatfda_docs/label/2006/050405s097lbl.pdf
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1];Associate Editor(s)-in-Chief: Abdurahman Khalil, M.D. [2]
